IGC Pharma, Inc. (IGC)

[NetworkNewsWire]

IGC Achieves Breakthrough with Potential to Prevent, Combat Alzheimer’s

India Globalization Capital (NYSE MKT: IGC), a first mover in the cannabis-based combination therapy space, recently announced that it is readying a line of cannabis-based medical dispensary products that target Alzheimer’s disease (http://nnw.fm/l2NJw). IGC is engineering genetic cell lines which demonstrate that, at various concentrations of tetrahydrocannabinol (THC), the protein Aß decreases as much as 40 percent without neuron damage. An article discussing this reads: “This compelling in vitro data, and the promise it shows as a preventative and powerful treatment against Alzheimer’s, makes IGC a company with valuation growth potential for investors. The commercial potential for an Alzheimer’s treatment or prevention drug is in the billions of dollars. Investors have made Alzheimer’s drugs a high biotechnology priority.”

To view the full article, visit http://nnw.fm/Fr2JN

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us